<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLOXURIDINE</span><br/>(flox-yoor'i-deen)<br/><span class="topboxtradename">FUDR<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antimetabolite</span>; <span class="classification">pyrimidine</span><br/><b>Prototype: </b>Fluorouracil<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Pyrimidine antagonist and cell-cycle specific. Catabolized to fluorouracil in the body; highly toxic by blocking an enzyme
         essential to normal DNA and RNA synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Proliferative cells of neoplasms are affected more than healthy tissue cells.</p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative agent in management of selected patients with GI metastasis to liver.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Carcinoma of breast, ovary, cervix, urinary bladder, and prostate not responsive to other antimetabolites.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Existing or recent viral infections. Pregnancy (category D); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Poor nutritional status, bone marrow depression, serious infections; high-risk patients: prior high-dose pelvic irradiation,
         use of alkylating agents; impaired kidney or liver function.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Carcinoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intraarterial</span> 0.10.6 mg/kg/d by continuous intraarterial infusion<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intraarterial Infusion</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute with 5 mL sterile distilled water for injection; further dilute with D5W or NS injection to a volume appropriate
                  for the infusion apparatus to be used.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> It is administered by pump to overcome pressure in large arteries and to ensure a uniform rate. Examine infusion site frequently
                  for signs of extravasation. If this occurs, stop infusion and restart in another vessel.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span>
<b>Allopurinol</b>, <b>cefepime</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Keep reconstituted solutions, which are stable at 2°8° C (36°46° F), for no more than 2 wk.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Vertigo, convulsions, depression, hemiplegia. <span class="typehead"> CV:</span>  Myocardial ischemia, angina. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, stomatitis,</span> diarrhea, cramps, anorexia, enteritis, gastritis, esophagopharyngitis. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Leukopenia</span>, <span class="speceff-common">thrombocytopenia.</span>
<span class="typehead">Skin:</span> Dermatitis, alopecia (usually reversible), <span class="speceff-common">erythema</span> or increased skin pigmentation (photosensitivity), dry skin, pruritic ulcerations, rash. <span class="typehead">Body as a Whole:</span> Hiccups, fever, epistaxis, decreased resistance to disease. <span class="typehead">Urogenital:</span> Renal insufficiency. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Metronidazole</b> may increase general floxuridine toxicity; may increase or decrease serum levels of <b>phenytoin,</b>
<b>fosphenytoin;</b>
<b>hydroxyurea</b> can decrease conversion to active metabolite. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Distributed to tumor, intestinal mucosa, bone marrow, liver, and CSF; probably crosses placenta. <span class="typehead">Metabolism:</span> Rapidly metabolized in liver to fluorouracil. <span class="typehead">Elimination:</span> 15% excreted in urine, 6080% excreted through lungs as carbon dioxide. <span class="typehead">Half-Life:</span> 16 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue therapy promptly with onset of any of the following: Stomatitis, esophagopharyngitis, intractable vomiting, diarrhea,
            leukopenia (WBC 3), or rapidly falling WBC count, thrombocytopenia (platelets 100,000/mm<sup>3</sup>), GI bleeding, hemorrhage from any site.
         </li>
<li>Lab tests: Obtain baseline and periodic total and differential leukocyte counts, Hct, platelet count, serum uric acid creatinine,
            and liver function tests.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that floxuridine sometimes causes temporary thinning of hair.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>